CIK-CAR.CD33

N/A

Report date: 2025/03/14 16:21:07

Base Information

Drug NameCIK-CAR.CD33
Drug Alias Nameanti-CD33 CAR CIK-cell therapy (Formula Pharmaceuticals)anti-CD33 CAR cytokine induced killer cell therapy (Formula Pharmaceuticals)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Cytokine-induced killer cellCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionMyeloid cell surface antigen CD33 modulators
TargetsMyeloid cell surface antigen CD33
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesFormula Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesCoImmune Inc
Inactive CompaniesFormula Gmbh
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A